Integrase inhibitors: A new treatment option for patients with human immunodeficiency virus infection

Pharmacotherapy

Volumn 28, Issue 1, 2008, Pages 90-101

  Correll, Todd ^a   Klibanov, Olga M ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Antiretrovirals; Elvitegravir; GS 9137; Integrase inhibitors; MK 0518; Raltegravir

Indexed keywords

ABACAVIR; ANTACID AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INTEGRASE INHIBITOR; LAMIVUDINE; MIDAZOLAM; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PLACEBO; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS DNA; VIRUS RNA;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME INHIBITION; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INJECTION SITE REACTION; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; PRURITUS; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VOMITING;

DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; ORGANIC CHEMICALS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 38049014447     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.1.90     Document Type: Review

References (27)

1. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. Atlanta, GA: Centers for Disease Control and Prevention, 2004.
2. Dubey S, Sayanarayana YD, Lavania H. Development of integrase inhibitors for treatment of AIDS: an overview Eur J Med Chem 2007;42:1159-68.
3. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369:1261-9.
4. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Presented at the 14th conference on retroviruses and opportunistic infections, Los Angeles, CA, February 25-28, 2007.
5. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Presented at the 14th conference on retroviruses and opportunistic infections, Los Angeles, CA, February 25-28, 2007.
6. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5.
7. Zolopa A, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients. Presented at the 14th conference on retroviruses and opportunistic infections, Los Angeles, CA, February 25-28, 2007.
8. Markowitz M, Nguyen BY, Gotuzzo F, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naïve HIV-1 infected patients. Presented at the 16th international AIDS conference, Toronto, Canada, August 13-18, 2006.
9. Zhu K, Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type-1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004;78(10): 5045-55.
10. Yoder KE, Bushman FD. Repair of gaps in retroviral DNA integration intermediates. J Virol 2000;74(23):11191-200.
11. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4(3):235-48.
12. Petry AS, Wenning LA, Laethem M, et al. Safety, tolerability and pharmacokinetics after single and multiple doses of MK-0518 in healthy subjects. Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
13. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43:509-15.
14. Miller M, Witmer M, Stillmock K, et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor. Presented at the 16th international AIDS conference, Toronto, Canada, August 13-18, 2006.
15. Kassahun K, McIntosh I, Hreniuk D, et al. Absorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers. Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
16. Iwamoto M, Wenning LA, Troyer MD, et al. Lack of a pharmacokinetic interaction of MK-0518 on midazolam (MDZ). Presented at the 8th international congress on drug therapy in HIV infection, Glasgow, United Kingdom, November 12-16, 2006.
17. Kawaguchi I, Ishikawa T, Ishibashi M, Irie S, Kakee A. Safety and pharmacokinetics of single oral dose JTK-303/GS-9137, a novel integrase inhibitor, in healthy volunteers. Presented at the 13th conference on retrovirus and opportunistic infections, Denver, CO, February 5-9, 2006.
18. Kearney BP, Mathias M, Zhong, L, et al. Pharmacokinetics/ pharmacodynamics of GS-9137, an HIV integrase inhibitor. Presented at the 7th international workshop on clinical pharmacology of HIV therapy, Lisbon, Portugal, April 20-22, 2006.
19. Jones C, Ledford R, Yu F, McColl D. Resistance profile of HIV-1 mutations in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Presented at the 14th conference on retroviruses and opportunistic infections, Los Angeles, CA, February 25-28, 2007.
20. Mistry GC, Wenning LA, Merschman S, et al. Atazanavir and ritonavir increase plasma levels of MK-0518. Presented at the 8th international congress on drug therapy in HIV infection, Glasgow, United Kingdom, November 12-16, 2006.
21. Wenning LA, Hanley H, Stone J, et al. Effect of tipranavir + ritonavir (tpv + rtv) on pharmacokinetics of MK-0518. Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
22. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of MK-0518. Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
23. Iwamoto M, Wenning LA, Liou SY, et al. Rifampin (RIF) modestly reduces plasma levels of MK-0518. Presented at the 8th international congress on drug therapy in HIV infection, Glasgow, United Kingdom, November 12-16, 2006.
24. Ramanthan S, Shen G, Hinkle J, Enejosa J, Kearney BP. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents. Presented at the 8th international workshop on clinical pharmacology of HIV therapy, Budapest, Hungary, April 16-18, 2007.
25. Ramanthan S, Shen G, Hinkle J, Enejosa J, Kearney BP. Lack of clinically relevant drug interactions between ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and stavudine, didanosine or abacavir. Presented at the 8th international workshop on clinical pharmacology of HIV therapy, Budapest, Hungary, April 16-18, 2007.
26. Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. Presented at the 16th international AIDS conference, Toronto, Canada, August 13-18, 2006.
27. Ramanathan S, Lagan K, Plummer A, et al. Lack of clinically relevant drug-drug interaction between the ritonavir-boosted HIV integrase inhibitor GS-9137/r and zidovudine. Presented at the 16th international AIDS conference, Toronto, Canada, August 13-18, 2006.